Last updated on June 2019

Efficacy and Safety of 2 Secukinumab Regimens in 90 kg or Higher Subjects With Moderate to Severe Chronic Plaque-type Psoriasis


Brief description of study

Demonstrate superiority of secukinumab high dose over standard dose in heavy body weight subjects with moderate to severe plaque psoriasis.

Detailed Study Description

A 52-week multicenter, randomized, double-blind, parallel-group trial in approximately 330 subjects with moderate to severe chronic plaque-type psoriasis of body weight 90 kg or higher at time of randomization.

The study consists of 4 periods: screening (up to 4 weeks), treatment Period 1 (16 weeks), treatment Period 2 (36 weeks), and post-treatment follow-up (8 weeks).

Subjects will be randomized using a 1:1 ratio to the following groups: Secukinumab 300 mg every 2 weeks; Secukinumab 300 mg every 4 weeks.

In addition, subjects from the 300 mg every 4 weeks group who do not achieve PASI 90 response at Week 16 will be randomized using a 1:1 ratio to either remain on secukinumab 300 mg every 4 weeks or receive secukinumab 300 mg every 2 weeks starting at Week 16, until the end of treatment.

Clinical Study Identifier: NCT03504852

Find a site near you

Start Over

Novartis Investigative Site

Birmingham, AL United States
  Connect »

Novartis Investigative Site

Phoenix, AZ United States
  Connect »

Novartis Investigative Site

Sacramento, CA United States
  Connect »

Novartis Investigative Site

San Diego, CA United States
  Connect »

Novartis Investigative Site

Santa Monica, CA United States
  Connect »

Novartis Investigative Site

Centennial, CO United States
  Connect »

Novartis Investigative Site

Ormond Beach, FL United States
  Connect »

Novartis Investigative Site

West Palm Beach, FL United States
  Connect »

Novartis Investigative Site

Alpharetta, GA United States
  Connect »

Novartis Investigative Site

Snellville, GA United States
  Connect »

Novartis Investigative Site

Indianapolis, IN United States
  Connect »

Novartis Investigative Site

New Albany, IN United States
  Connect »

Novartis Investigative Site

Louisville, KY United States
  Connect »

Novartis Investigative Site

Owensboro, KY United States
  Connect »

Novartis Investigative Site

Fridley, MN United States
  Connect »

Novartis Investigative Site

Saint Joseph, MO United States
  Connect »

Novartis Investigative Site

East Windsor, NJ United States
  Connect »

Novartis Investigative Site

Forest Hills, NY United States
  Connect »

Novartis Investigative Site

New York, NY United States
  Connect »

Novartis Investigative Site

Charlotte, NC United States
  Connect »

Novartis Investigative Site

Winston-Salem, NC United States
  Connect »

Novartis Investigative Site

Fairborn, OH United States
  Connect »

Novartis Investigative Site

Oregon City, OR United States
  Connect »

Novartis Investigative Site

Portland, OR United States
  Connect »

Novartis Investigative Site

Charleston, SC United States
  Connect »

Novartis Investigative Site

Houston, TX United States
  Connect »

Novartis Investigative Site

Mesquite, TX United States
  Connect »

Novartis Investigative Site

Pflugerville, TX United States
  Connect »

Novartis Investigative Site

San Antonio, TX United States
  Connect »

Novartis Investigative Site

Norfolk, VA United States
  Connect »

Novartis Investigative Site

Wenatchee, WA United States
  Connect »

Novartis Investigative Site

Madison, WI United States
  Connect »

Novartis Investigative Site

Chelyabinsk, Russian Federation
  Connect »

Novartis Investigative Site

Ekaterinburg, Russian Federation
  Connect »

Novartis Investigative Site

Kazan, Russian Federation
  Connect »

Novartis Investigative Site

Krasnodar, Russian Federation
  Connect »

Novartis Investigative Site

Lipetsk, Russian Federation
  Connect »

Novartis Investigative Site

Saint Petersburg, Russian Federation
  Connect »

Novartis Investigative Site

Saratov, Russian Federation
  Connect »